메뉴 건너뛰기




Volumn 27, Issue 28, 2009, Pages 4747-4753

Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: A collaborative study of the French CBF-AML intergroup

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; CORE BINDING FACTOR;

EID: 70350450588     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.0674     Document Type: Article
Times cited : (117)

References (41)
  • 1
    • 2942602706 scopus 로고    scopus 로고
    • Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11
    • Shigesada K, van de Sluis B, Liu PP: Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene 23:4297-4307, 2004
    • (2004) Oncogene , vol.23 , pp. 4297-4307
    • Shigesada, K.1    van de Sluis, B.2    Liu, P.P.3
  • 2
    • 2942516037 scopus 로고    scopus 로고
    • The 8;21 translocation in leukemogenesis
    • Peterson LF, Zhang DE: The 8;21 translocation in leukemogenesis. Oncogene 23:4255-4262, 2004
    • (2004) Oncogene , vol.23 , pp. 4255-4262
    • Peterson, L.F.1    Zhang, D.E.2
  • 3
    • 38949105508 scopus 로고    scopus 로고
    • Gatekeeper function of the RUNX1 transcription factor in acute leukemia
    • Niebuhr B, Fischer M, Tager M, et al: Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells Mol Dis 40:211-218, 2008
    • (2008) Blood Cells Mol Dis , vol.40 , pp. 211-218
    • Niebuhr, B.1    Fischer, M.2    Tager, M.3
  • 4
    • 0032793987 scopus 로고    scopus 로고
    • Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
    • Byrd JC, Dodge RK, Carroll A, et al: Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767-3775, 1999
    • (1999) J Clin Oncol , vol.17 , pp. 3767-3775
    • Byrd, J.C.1    Dodge, R.K.2    Carroll, A.3
  • 5
    • 33748747555 scopus 로고    scopus 로고
    • The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
    • Appelbaum FR, Kopecky KJ, Tallman MS, et al: The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135:165-173, 2006
    • (2006) Br J Haematol , vol.135 , pp. 165-173
    • Appelbaum, F.R.1    Kopecky, K.J.2    Tallman, M.S.3
  • 6
    • 17544388046 scopus 로고    scopus 로고
    • Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
    • Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
    • (1998) Cancer Res , vol.58 , pp. 4173-4179
    • Bloomfield, C.D.1    Lawrence, D.2    Byrd, J.C.3
  • 7
    • 1842614240 scopus 로고    scopus 로고
    • Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461
    • Byrd JC, Ruppert AS, Mrozek K, et al: Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol 22:1087-1094, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 1087-1094
    • Byrd, J.C.1    Ruppert, A.S.2    Mrozek, K.3
  • 8
    • 0035469883 scopus 로고    scopus 로고
    • The predictive value of hierarchical cytogenetic classifi-cation in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
    • Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classifi-cation in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
    • (2001) Blood , vol.98 , pp. 1312-1320
    • Grimwade, D.1    Walker, H.2    Harrison, G.3
  • 9
    • 3042782698 scopus 로고    scopus 로고
    • The benefit of induction chemotherapy in patients age > or = 75 years
    • Vey N, Coso D, Bardou VJ, et al: The benefit of induction chemotherapy in patients age > or = 75 years. Cancer 101:325-331, 2004
    • (2004) Cancer , vol.101 , pp. 325-331
    • Vey, N.1    Coso, D.2    Bardou, V.J.3
  • 10
    • 4644234164 scopus 로고    scopus 로고
    • The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups
    • Schoch C, Kern W, Schnittger S, et al: The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 89:1082-1090, 2004
    • (2004) Haematologica , vol.89 , pp. 1082-1090
    • Schoch, C.1    Kern, W.2    Schnittger, S.3
  • 11
    • 33745191374 scopus 로고    scopus 로고
    • Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
    • Farag SS, Archer KJ, Mrozek K, et al: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108:63-73, 2006
    • (2006) Blood , vol.108 , pp. 63-73
    • Farag, S.S.1    Archer, K.J.2    Mrozek, K.3
  • 12
    • 24944464648 scopus 로고    scopus 로고
    • Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study
    • Marcucci G, Mrozek K, Ruppert AS, et al: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 23:5705-5717, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 5705-5717
    • Marcucci, G.1    Mrozek, K.2    Ruppert, A.S.3
  • 13
    • 0038156371 scopus 로고    scopus 로고
    • Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup
    • Delaunay J, Vey N, Leblanc T, et al: Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood 102:462-469, 2003
    • (2003) Blood , vol.102 , pp. 462-469
    • Delaunay, J.1    Vey, N.2    Leblanc, T.3
  • 14
    • 0034010518 scopus 로고    scopus 로고
    • Measuring comorbidity in older cancer patients
    • Extermann M: Measuring comorbidity in older cancer patients. Eur J Cancer 36:453-471, 2000
    • (2000) Eur J Cancer , vol.36 , pp. 453-471
    • Extermann, M.1
  • 15
    • 33644521267 scopus 로고    scopus 로고
    • Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome
    • Kantarjian H, O'Brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 106:1090-1098, 2006
    • (2006) Cancer , vol.106 , pp. 1090-1098
    • Kantarjian, H.1    O'Brien, S.2    Cortes, J.3
  • 16
    • 33947499161 scopus 로고    scopus 로고
    • Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
    • Etienne A, Esterni B, Charbonnier A, et al: Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 109:1376-1383, 2007
    • (2007) Cancer , vol.109 , pp. 1376-1383
    • Etienne, A.1    Esterni, B.2    Charbonnier, A.3
  • 17
    • 0017162163 scopus 로고
    • Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group
    • Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
    • (1976) Br J Haematol , vol.33 , pp. 451-458
    • Bennett, J.M.1    Catovsky, D.2    Daniel, M.T.3
  • 18
    • 36349005328 scopus 로고    scopus 로고
    • Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: The BGMT 95 trial results
    • Pigneux A, Perreau V, Jourdan E, et al: Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: The BGMT 95 trial results. Haematologica 92:1327-1334, 2007
    • (2007) Haematologica , vol.92 , pp. 1327-1334
    • Pigneux, A.1    Perreau, V.2    Jourdan, E.3
  • 19
    • 0004313674 scopus 로고    scopus 로고
    • A placebocontrolled study of recombinant human granulocytemacrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM)
    • Witz F, Sadoun A, Perrin MC, et al: A placebocontrolled study of recombinant human granulocytemacrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 91:2722-2730, 1998
    • (1998) Blood , vol.91 , pp. 2722-2730
    • Witz, F.1    Sadoun, A.2    Perrin, M.C.3
  • 20
    • 3042667021 scopus 로고    scopus 로고
    • Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM data
    • suppl 1
    • Witz F, Harousseau JL, Guilhot F, et al: Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM data. Ann Hematol 83:S55-S57, 2004 (suppl 1)
    • (2004) Ann Hematol , vol.83
    • Witz, F.1    Harousseau, J.L.2    Guilhot, F.3
  • 21
    • 4944234928 scopus 로고    scopus 로고
    • Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study
    • Castaigne S, Chevret S, Archimbaud E, et al: Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 104:2467-2474, 2004
    • (2004) Blood , vol.104 , pp. 2467-2474
    • Castaigne, S.1    Chevret, S.2    Archimbaud, E.3
  • 22
    • 34250157761 scopus 로고    scopus 로고
    • Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
    • Gardin C, Turlure P, Fagot T, et al: Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109:5129-5135, 2007
    • (2007) Blood , vol.109 , pp. 5129-5135
    • Gardin, C.1    Turlure, P.2    Fagot, T.3
  • 23
    • 33750136033 scopus 로고    scopus 로고
    • Noninfusional versus intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: Final results of the EORTC-GIMEMA AML-13 randomized phase III trial
    • Jehn U, Suciu S, Thomas X, et al: Noninfusional versus intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: Final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia 20: 1723-1730, 2006
    • (2006) Leukemia , vol.20 , pp. 1723-1730
    • Jehn, U.1    Suciu, S.2    Thomas, X.3
  • 24
    • 1542753559 scopus 로고    scopus 로고
    • Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    • Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 4642-4649
    • Cheson, B.D.1    Bennett, J.M.2    Kopecky, K.J.3
  • 25
    • 0037093053 scopus 로고    scopus 로고
    • A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup
    • Nguyen S, Leblanc T, Fenaux P, et al: A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood 99:3517-3523, 2002
    • (2002) Blood , vol.99 , pp. 3517-3523
    • Nguyen, S.1    Leblanc, T.2    Fenaux, P.3
  • 26
    • 9344237642 scopus 로고    scopus 로고
    • Fiftyone patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor
    • Schoch C, Haase D, Haferlach T, et al: Fiftyone patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor. Leukemia 10:1288-1295, 1996
    • (1996) Leukemia , vol.10 , pp. 1288-1295
    • Schoch, C.1    Haase, D.2    Haferlach, T.3
  • 27
    • 4644288302 scopus 로고    scopus 로고
    • Schlenk RF, Benner A, Krauter J, et al: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741-3750, 2004
    • Schlenk RF, Benner A, Krauter J, et al: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741-3750, 2004
  • 28
    • 34249340637 scopus 로고    scopus 로고
    • Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia
    • Mrozek K, Bloomfield CD: Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 169-177, 2006
    • (2006) Hematology Am Soc Hematol Educ Program , vol.169-177
    • Mrozek, K.1    Bloomfield, C.D.2
  • 29
    • 33744487375 scopus 로고    scopus 로고
    • Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
    • Boissel N, Leroy H, Brethon B, et al: Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965-970, 2006
    • (2006) Leukemia , vol.20 , pp. 965-970
    • Boissel, N.1    Leroy, H.2    Brethon, B.3
  • 30
    • 33748467435 scopus 로고    scopus 로고
    • Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): A Cancer and Leukemia Group B Study
    • Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 3904-3911
    • Paschka, P.1    Marcucci, G.2    Ruppert, A.S.3
  • 31
    • 33846433493 scopus 로고    scopus 로고
    • The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
    • Giles FJ, Borthakur G, Ravandi F, et al: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624-627, 2007
    • (2007) Br J Haematol , vol.136 , pp. 624-627
    • Giles, F.J.1    Borthakur, G.2    Ravandi, F.3
  • 32
    • 57549098626 scopus 로고    scopus 로고
    • Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
    • Malfuson JV, Etienne A, Turlure P, et al: Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 93:1806-1813, 2008
    • (2008) Haematologica , vol.93 , pp. 1806-1813
    • Malfuson, J.V.1    Etienne, A.2    Turlure, P.3
  • 33
    • 0032751381 scopus 로고    scopus 로고
    • Management of acute myeloid leukemia in elderly patients
    • Hiddemann W, Kern W, Schoch C, et al: Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17:3569-3576, 1999
    • (1999) J Clin Oncol , vol.17 , pp. 3569-3576
    • Hiddemann, W.1    Kern, W.2    Schoch, C.3
  • 34
    • 23844507573 scopus 로고    scopus 로고
    • Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
    • Rowe JM: Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)? Leukemia 19:1324-1327, 2005
    • (2005) Leukemia , vol.19 , pp. 1324-1327
    • Rowe, J.M.1
  • 35
    • 51649089123 scopus 로고    scopus 로고
    • Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
    • Candoni A, Martinelli G, Toffoletti E, et al: Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 32:1800-1808, 2008
    • (2008) Leuk Res , vol.32 , pp. 1800-1808
    • Candoni, A.1    Martinelli, G.2    Toffoletti, E.3
  • 36
    • 58149220896 scopus 로고    scopus 로고
    • Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival
    • Borthakur G, Kantarjian H, Wang X, et al: Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 113:3181-3185, 2008
    • (2008) Cancer , vol.113 , pp. 3181-3185
    • Borthakur, G.1    Kantarjian, H.2    Wang, X.3
  • 37
    • 33745586575 scopus 로고    scopus 로고
    • Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    • Faderl S, Verstovsek S, Cortes J, et al: Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45-51, 2006
    • (2006) Blood , vol.108 , pp. 45-51
    • Faderl, S.1    Verstovsek, S.2    Cortes, J.3
  • 38
    • 38349185874 scopus 로고    scopus 로고
    • HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: Collaborative study between the German AML Intergroup and CIBMTR
    • Schlenk RF, Pasquini MC, Perez WS, et al: HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: Collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant 14:187-196, 2008
    • (2008) Biol Blood Marrow Transplant , vol.14 , pp. 187-196
    • Schlenk, R.F.1    Pasquini, M.C.2    Perez, W.S.3
  • 39
    • 27244434510 scopus 로고    scopus 로고
    • Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment
    • Blaise DP, Michel Boiron J, Faucher C, et al: Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 104:1931-1938, 2005
    • (2005) Cancer , vol.104 , pp. 1931-1938
    • Blaise, D.P.1    Michel Boiron, J.2    Faucher, C.3
  • 40
    • 38949163678 scopus 로고    scopus 로고
    • FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia
    • Kim HG, Kojima K, Swindle CS, et al: FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. Blood 111:1567-1574, 2008
    • (2008) Blood , vol.111 , pp. 1567-1574
    • Kim, H.G.1    Kojima, K.2    Swindle, C.S.3
  • 41
    • 55749083387 scopus 로고    scopus 로고
    • Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
    • Mrózek K, Marcucci G, Paschka P, et al: Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 20:711-718, 2008
    • (2008) Curr Opin Oncol , vol.20 , pp. 711-718
    • Mrózek, K.1    Marcucci, G.2    Paschka, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.